Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Treatment entities : Intellia therapeutics, inc. save search
Intellia Therapeutics Announces First Patient Dosed in the Phase 3 MAGNITUDE Study of NTLA-2001 as a Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathy
Published: 2024-03-18 (Crawled : 12:00) - globenewswire.com
NTLA | $21.27 -1.21% 230K
|
Health Technology
|
| O: -0.88%
H: 0.0%
C: -2.42%
ntla-2001 first treatment therapeutics study
Intellia Therapeutics to Present Updated Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis and Hold Conference Call to Discuss Third Quarter 2023 Earnings in November
Published: 2023-10-26 (Crawled : 12:00) - globenewswire.com
NTLA | $21.27 -1.21% 230K
|
Health Technology
|
| O: 1.31%
H: 4.57%
C: 1.21%
ntla-2001 conference treatment ongoing therapeutics study
Intellia Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application to Initiate a Pivotal Phase 3 Trial of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy
Published: 2023-10-18 (Crawled : 11:00) - globenewswire.com
NTLA | $21.27 -1.21% 230K
|
Health Technology
|
| O: 1.58%
H: 0.44%
C: -5.25%
ntla-2001 fda drug treatment clearance application trial therapeutics
Intellia Therapeutics Receives Priority Medicines (PRIME) Designation From the European Medicines Agency for NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema
Published: 2023-10-13 (Crawled : 12:30) - globenewswire.com
NTLA | $21.27 -1.21% 230K
|
Health Technology
|
| O: 0.35%
H: 3.41%
C: 2.83%
ntla-2002 crispr treatment designation therapeutics
Regeneron and Intellia Announce Expanded Research Collaboration to Develop CRISPR-Based Therapies for the Treatment of Neurological and Muscular Diseases
Published: 2023-10-03 (Crawled : 11:00) - globenewswire.com
SNY | News | $46.82 -1.82% 510K
|
Health Technology
|
| O: -1.41%
H: 0.0%
C: 0.0%
REGN | News | $911.73 0.49% 97K
|
Health Technology
|
| O: -0.74%
H: 0.21%
C: -0.45%
NTLA | $21.27 -1.21% 230K
|
Health Technology
|
| O: -0.1%
H: 1.97%
C: 1.02%
treatment research collaboration neurological
Intellia Therapeutics Announces New Positive Clinical Data from Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema (HAE)
Published: 2023-06-11 (Crawled : 16:20) - globenewswire.com
NTLA | $21.27 -1.21% 230K
|
Health Technology
| Email alert
Add to watchlist
ntla-2002 crispr positive treatment therapeutics study
Intellia Therapeutics to Present Updated Interim Data from Ongoing Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Hybrid Congress 2023
Published: 2023-05-31 (Crawled : 12:01) - globenewswire.com
NTLA | $21.27 -1.21% 230K
|
Health Technology
|
| O: -0.75%
H: 3.7%
C: -0.03%
ntla-2002 treatment ongoing therapeutics study
Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to NTLA-2002 for the Treatment of Hereditary Angioedema
Published: 2023-03-21 (Crawled : 12:00) - globenewswire.com
NTLA | $21.27 -1.21% 230K
|
Health Technology
|
| O: 1.38%
H: 2.94%
C: 2.55%
ntla-2002 fda granted treatment designation therapeutics therapy
Intellia Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for NTLA-2002, an In Vivo CRISPR-Based Investigational Therapy for the Treatment of Hereditary Angioedema (HAE)
Published: 2023-03-02 (Crawled : 12:00) - globenewswire.com
NTLA | $21.27 -1.21% 230K
|
Health Technology
|
| O: 7.68%
H: 3.12%
C: 0.25%
ntla-2002 treatment fda clearance drug application therapeutics therapy
Intellia Therapeutics Awarded Innovation Passport in the United Kingdom for NTLA-2002, an Investigational Genome Editing Treatment for Hereditary Angioedema
Published: 2023-01-11 (Crawled : 13:00) - globenewswire.com
NTLA | $21.27 -1.21% 230K
|
Health Technology
|
| O: 0.24%
H: 1.56%
C: -1.03%
ntla-2002 treatment therapeutics innovation hereditary angioedema
SparingVision’s lead asset SPVN06 clears IND application in the US for the treatment of retinitis pigmentosa
Published: 2022-12-01 (Crawled : 19:00) - biospace.com/
NTLA | $21.27 -1.21% 230K
|
Health Technology
|
| O: -6.84%
H: 0.13%
C: -4.46%
spvn06 treatment application
Intellia Therapeutics Presents New Interim Data from First-in-Human Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the American College of Allergy, Asthma & Immunology 2022 Annual Scientific Meeting
Published: 2022-11-12 (Crawled : 00:20) - globenewswire.com
NTLA | $21.27 -1.21% 230K
|
Health Technology
| Email alert
Add to watchlist
ntla-2002 treatment immunology meeting therapeutics study hereditary angioedema
Intellia Presents Updated Interim Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis at the American Heart Association Scientific Sessions 2022
Published: 2022-11-05 (Crawled : 20:20) - globenewswire.com
NTLA | $21.27 -1.21% 230K
|
Health Technology
| Email alert
Add to watchlist
ntla-2001 sessions treatment ongoing arm crispr heart therapy study
Intellia Therapeutics to Present Updated Interim Clinical Data from Ongoing Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema at the 2022 ACAAI Annual Scientific Meeting
Published: 2022-10-31 (Crawled : 12:00) - globenewswire.com
NTLA | $21.27 -1.21% 230K
|
Health Technology
|
| O: -0.09%
H: 1.61%
C: -2.22%
ntla-2002 treatment ongoing meeting therapeutics study hereditary angioedema
Intellia and Regeneron Announce Initial Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis
Published: 2022-09-16 (Crawled : 12:00) - prnewswire.com
SNYNF | News | $94.25 480
|
Health Technology
|
| O: 0.74%
H: 0.91%
C: -0.74%
SNY | News | $46.82 -1.82% 510K
|
Health Technology
|
| O: -0.52%
H: 0.0%
C: 0.0%
REGN | News | $911.73 0.49% 97K
|
Health Technology
|
| O: 0.62%
H: 1.12%
C: 0.01%
NTLA | $21.27 -1.21% 230K
|
Health Technology
|
| O: -3.76%
H: 0.36%
C: -0.44%
ntla-2001 treatment ongoing crispr therapy study
Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-2002, an Investigational CRISPR Therapy for the Treatment of Hereditary Angioedema
Published: 2022-09-01 (Crawled : 21:00) - biospace.com/
NTLA | $21.27 -1.21% 230K
|
Health Technology
|
| O: -3.35%
H: 3.46%
C: 3.31%
ntla-2002 treatment fda designation drug crispr therapeutics therapy hereditary angioedema
Intellia Therapeutics to Present Interim Clinical Data from Ongoing Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema at the 2022 Bradykinin Symposium
Published: 2022-08-23 (Crawled : 14:20) - globenewswire.com
NTLA | $21.27 -1.21% 230K
|
Health Technology
|
| O: 0.87%
H: 11.13%
C: 10.67%
ntla-2002 treatment symposium therapeutics study hereditary angioedema phase 1
Intellia and Regeneron Present Updated Interim Data from Phase 1 Study of CRISPR-based NTLA-2001 for the Treatment of Transthyretin (ATTR)
Published: 2022-06-24 (Crawled : 12:00) - biospace.com/
SNYNF | News | $94.25 480
|
Health Technology
|
| O: 8.01%
H: 0.0%
C: 0.0%
SNY | News | $46.82 -1.82% 510K
|
Health Technology
|
| O: 3.49%
H: 0.0%
C: 0.0%
REGN | News | $911.73 0.49% 97K
|
Health Technology
|
| O: 0.77%
H: 0.18%
C: 0.07%
NTLA | $21.27 -1.21% 230K
|
Health Technology
|
| O: 3.45%
H: 5.18%
C: 1.71%
ntla-2001 treatment phase 1
Intellia and Regeneron Present Updated Interim Data from Phase 1 Study of CRISPR-based NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis Demonstrating that Deep Serum TTR Reductions Remained Durable After a Single Dose
Published: 2022-06-24 (Crawled : 12:00) - globenewswire.com
SNYNF | News | $94.25 480
|
Health Technology
|
| O: 8.01%
H: 0.0%
C: 0.0%
SNY | News | $46.82 -1.82% 510K
|
Health Technology
|
| O: 3.49%
H: 0.0%
C: 0.0%
REGN | News | $911.73 0.49% 97K
|
Health Technology
|
| O: 0.77%
H: 0.18%
C: 0.07%
NTLA | $21.27 -1.21% 230K
|
Health Technology
|
| O: 3.45%
H: 5.18%
C: 1.71%
ntla-2001 treatment phase 1
Intellia Therapeutics to Present Updated Interim Clinical Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis at the International Liver Congress™ 2022
Published: 2022-06-08 (Crawled : 12:00) - globenewswire.com
REGN | News | $911.73 0.49% 97K
|
Health Technology
|
| O: 2.14%
H: 0.78%
C: -1.66%
NTLA | $21.27 -1.21% 230K
|
Health Technology
|
| O: 7.15%
H: 14.41%
C: 8.79%
ntla-2001 treatment liver therapeutics international phase 1
Gainers vs Losers
| 59% | 41% |
Top 10 Gainers
CSSE 4 | $0.3686 142.02% 76M
|
Consumer Services
CZOO | $11.685 134.17% 7.6M
|
BOF | $1.93 64.96% 55M
|
AMST | $3.14 57.0% 59M
|
Technology Services
TROO | $1.57 44.04% 2.8M
|
Manufacturing
LICN | $0.7885 40.8% 11M
|
MULN | News | $3.7 35.53% 6.4M
|
Information
WHLM | $6.61 30.12% 400K
|
Commercial Services
RILY | $27.91 28.5% 8.9M
|
Finance
RBBN 4 | $3.25 26.46% 1.5M
|
Electronic Technology
Your saved searches
Save your searches and get alerts when important news are released.